KALA BIO, Inc..
KALA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. The company's primary focus is on developing therapies for rare and severe ophthalmic conditions. They utilize their proprietary Mucus P...Show More
Better Health for All
-50
KALA.US's core business is entirely devoted to health improvement, focusing on innovative therapies for eye diseases, with two FDA-approved products, EYSUVIS and INVELTYS, for dry eye disease and post-operative ocular inflammation, respectively.
1
However, EYSUVIS has reported adverse drug reactions, with 5% of patients experiencing instillation site pain, and carries contraindications and warnings about potential severe side effects like glaucoma or cataracts with prolonged use.
2
While EYSUVIS is available through commercial formularies like Cigna, there is no evidence of pricing relative to production cost or specific discount programs, nor is there data on the percentage of those in need reached.
3
KALA.US aims to deliver EYSUVIS to millions of dry eye disease sufferers in the U.S., but there is no specific data on the percentage of vulnerable populations reached.
4
The company's R&D expenses were $5.2M in Q3 2024, $5.3M in Q2 2024, and $6.4M in Q1 2024, with total grant income of $1.9M in Q3 2024, indicating that R&D investment is a significant portion of its limited revenue, but the percentage of revenue is not provided.
5
The ongoing CHASE Phase 2b trial for KPI-012 had its topline readout moved from Q1 2025 to Q2 2025, and there is no information on trial diversity or full results transparency.
6
Fair Money & Economic Opportunity
0
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for eye diseases.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its operations. No evidence was found to score any KPI against the 'Fair Money & Economic Opportunity' value.
Fair Pay & Worker Respect
0
No evidence available to assess KALA BIO, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess KALA BIO, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No data could be extracted from the provided article due to throttling, preventing assessment against any of the KPIs.
1
Kind to Animals
0
The provided articles do not contain specific, concrete data points regarding KALA BIO, Inc.'s performance across any of the 'Kind to Animals' KPIs. explicitly states that quantitative data on cruelty-free certification, alternative testing, humane certifications, wildlife conservation, ethical ingredient substitution, supplier audits, cage-free sourcing, animal testing volume, innovation investment, animal agriculture ethics, and public policy engagement are not provided.
1
Articles and discuss FDA regulatory actions and policy changes related to animal testing, which are external to KALA BIO, Inc. and do not provide evidence of the company's own practices or outcomes.
2
No War, No Weapons
0
No specific, concrete data points were found in the provided articles for KALA.US regarding any of the 'No War, No Weapons' KPIs.
1
The articles describe KALA BIO, Inc. as a clinical-stage biopharmaceutical company focused on eye diseases and explicitly state that no relevant data for the 'No War, No Weapons' value was available.
2
Planet-Friendly Business
0
KALA BIO, Inc. does not publicly report quantitative data for any of the planet-friendly business metrics.
1
There is no information available regarding total Scope 1, 2, and 3 greenhouse gas emissions, science-based carbon reduction targets, renewable energy consumption, water use per revenue, green building certifications, or waste diversion rates.
2
Similarly, data on capital expenditure alignment with the EU Sustainable Taxonomy, lifecycle impact assessments, recycled to virgin material ratios, carbon offset quality, climate-positive initiatives, supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policies, environmental compliance violations, environmental impact assessments, net-zero targets, TCFD alignment, climate scenario analysis, stranded asset transparency, water sourcing from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing is not provided in the available articles.
3
Respect for Cultures & Communities
0
No specific sustainability data related to respect for cultures and communities is available for KALA.US in the provided articles.
1
Both articles indicate a complete absence of relevant sustainability metrics for the company, with one explicitly stating 'Sustainability data is currently not available for KALA'.
2
Safe & Smart Tech
0
The provided article is a privacy statement from April 27, 2015.
1
It explicitly states that no data is provided on KALA BIO, Inc.'s security practices, investments, certifications, or compliance with regulations.
2
Therefore, no specific, concrete data points or facts relevant to any of the Safe & Smart Tech KPIs are available in the evidence to assign scores.
Zero Waste & Sustainable Products
0
No specific, concrete information regarding KALA BIO, Inc.'s waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs was found in the provided articles.
1